CTSB and Parkinson disease: Moreover, LRRK2 G2019S decreases the activity of lysosomal enzymes, including cathepsins B and L, indicating that the inhibitory effect of LRRK2 G2019S on α-Syn degradation could underlie the pathogenesis of aberrant α-Syn aggregation in PD with LRRK2 mutation [174].